Dostarlimab, also known as Jemperli, is set to revolutionize treatment for hundreds of women battling womb cancer as it becomes available on the NHS across England starting Tuesday. This immunotherapy drug, used in conjunction with chemotherapy, targets specific proteins on cancer cells, aiding the immune system in combating them.
Following approval by the National Institute for Health and Care Excellence (Nice) in 2022, NHS England is rolling out Dostarlimab, offering hope to up to 200 eligible patients annually. Studies indicate that when combined with chemotherapy, this monoclonal antibody can significantly prolong life expectancy.
Administered intravenously over thirty minutes, under medical supervision, Dostarlimab represents a promising advancement in cancer treatment, potentially enhancing both the quality and duration of patients’ lives.
Across the UK, womb-related cancers contribute to 9,700 new cases and 2,400 deaths annually, as reported by Cancer Research. Among these cancers, endometrial cancer and uterine sarcoma are the most prevalent forms.
Clinical trials have demonstrated promising results for Jemperli, with 64% of patients undergoing treatment alongside chemotherapy experiencing no cancer progression after one year. This rate is more than double the 24% observed with chemotherapy alone.
Dostarlimab, authorized by the Medicines and Healthcare Products Regulatory Agency (MHRA) in October, offers a beacon of hope as the first-line treatment for primary advanced or recurrent endometrial cancer. Its approval marks a significant milestone in combating womb-related cancers and extending patients’ life expectancy when used in conjunction with chemotherapy.
The drug’s primary side effects include underactive thyroid glands, skin rashes, dry skin, high temperature or fever, and elevated liver enzyme levels in the blood.
Prof Peter Clark, NHS England’s cancer drugs fund (CDF) lead, expressed optimism about the drug’s rollout, stating, “The rollout of this drug as a first-line treatment on the NHS is great news for patients living with this type of womb cancer – this new immunotherapy could offer hundreds of women the hope of precious extra time to live well before their cancer progresses.”
Helen Knight, the director of medicines evaluation at Nice, emphasized the impact of advanced or recurrent womb cancer on quality of life and the limited treatment options available.
She added, “We are focused on delivering what matters most and getting care to those who need it fast, so I am delighted this treatment option will be made quickly available through the CDF, enabling people with this type of cancer to enjoy more precious time with their families and loved ones.”
